As part of a new collaboration, Iktos’ generative design technology and Curreio’s cryo-electron microscopy (cryo-EM) platform will be combined to design novel preclinical drug candidates for an undisclosed target.
Iktos’ Makya generative AI technology aims to bring new insights and directions into the molecular discovery process by automatically designing virtual novel molecules that have desired activities for treating a given disease.
In the context of the collaboration, Iktos’ generative AI technology will be combined with structure-based modelling, using insights produced thanks to Curreio’s cryo-EM platform to design structures maximising protein-ligand interaction and with high probability of meeting the project’s Target Product Profile (TPP).
Structural analysis technology using cryo-EM was awarded the Nobel Prize in Chemistry in 2017. In particular, single-particle structure analysis using Cryo-EM is an analytical technique with many advantages, such as no need for crystallisation and the obtaining of structures in aqueous solution.
“We are thrilled to enter into a research collaboration with Curreio, a specialist in structural analysis of biomolecules and to combine our technology platforms to accelerate structure-based drug discovery together,” said Yann Gaston-Mathé, Co-founder and CEO of Iktos.
“We have high hopes that this joint research will greatly accelerate our structure-based drug design (SBDD) efforts,” added Motoki Nakai, Founder and CEO of Curreio.
